In the last trading session, 1.63 million shares of the Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) were traded, and its beta was 1.80. Most recently the company’s share price was $1.92, and it changed around -$0.24 or -11.11% from the last close, which brings the market valuation of the company to $136.83M. ZNTL currently trades at a discount to its 52-week high of $18.07, offering almost -841.15% off that amount. The share price’s 52-week low was $1.61, which indicates that the current value has risen by an impressive 16.15% since then. We note from Zentalis Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 4.06 million shares, with the 3-month average coming to 1.87 million.
Zentalis Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.09. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 6 recommended ZNTL as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Zentalis Pharmaceuticals Inc is expected to report earnings per share of -0.68 for the current quarter.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) trade information
Instantly ZNTL has showed a red trend with a performance of -11.11% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.3550 on recent trading dayincreased the stock’s daily price by 18.47%. The company’s shares are currently down -36.63% year-to-date, but still up 10.34% over the last five days. On the other hand, Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) is -35.79% down in the 30-day period. We can see from the shorts that 5.08 million shares have been sold at a short interest cover period of 3.46 day(s).
The consensus price target as assigned by Wall Street analysts is $10, which translates to bulls needing to increase their stock price by 80.8% from its current value. Analyst projections state that ZNTL is forecast to be at a low of $4 and a high of $55.
Forecasts for the next quarter put sales growth at -100.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -50.05%. Zentalis Pharmaceuticals Inc earnings are expected to increase by 44.78% in 2025, but the outlook is positive 17.67% per year for the next five years.
ZNTL Dividends
Zentalis Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in March.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 13.82% of Zentalis Pharmaceuticals Inc shares, and 98.92% of them are in the hands of institutional investors. The stock currently has a share float of 114.79%. Zentalis Pharmaceuticals Inc stock is held by 184.0 institutions, with MATRIX CAPITAL MANAGEMENT COMPANY, LP being the largest institutional investor. By 2024-06-30, it held 19.6902% of the shares, which is about 13.96 million shares worth $57.1 million.
FMR LLC, with 12.2383% or 8.68 million shares worth $35.49 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Mutual Fund Ser Tr-Eventide Gilead Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 4.95 shares worth $9.5 million, making up 6.94% of all outstanding shares. On the other hand, Mutual Fund Ser Tr-Eventide Gilead Fund held roughly 3.58 shares worth around $6.88 million, which represents about 5.03% of the total shares outstanding.
